A treatment system for performing a treatment on a patient may include a treatment fluid preparation device having a pump connected by a fluid channel to a reservoir of a source fluid, the pump conveying the source fluid from the reservoir, through a filter, and combining the source fluid with a concentrate by pumping the source fluid with the concentrate to form a treatment fluid in a batch container. The treatment fluid preparation device may have a controller that controls a heater, the pump, and a memory. The controller starts the heater to warm the treatment fluid in the batch container at a time that is responsive to the treatment time stored in the memory. The controller also detects a pressure property of the filter to determine its integrity and outputs an indication of a failed batch if the pressure property indicates the integrity of the filter is insufficient.

Hollow-fibre membrane having at least one first curl in the form of a first wave which is characterized by a first oscillation plane and a first wavelength and at least one second curl in the form of a second wave which is characterized by a second oscillation plane and a second wavelength, characterized in that the first oscillation plane and the second oscillation plane confine an angle with one another which is different from zero.

The object of the present invention is a new cryopolymerization process that allows to obtain crosslinked polymeric materials in the form of a macroporous gel (cryogel) capable of sequestering (neutralize) the anticoagulant heparin, its low molecular weight derivatives (LMWH and ULMWH) and heparinoids, from aqueous solutions, physiological solutions and biological fluids, such as whole blood, serum and plasma.

A further object of the invention are also crosslinked polymeric materials in the form of a macroporous gel (cryogel) obtained by the cryopolymerization process of the invention that, thanks to said specific process, result to be comprised of varying proportions of HEMA and HEMA-R monomers. The molar ratio between the components (HEMA/HEMA-R) may vary between 99.9% HEMA:0.1% HEMA-R and 0.1% HEMA:99.9% HEMA-R.

Object of the invention is also the use of crosslinked polymeric materials in the form of a macroporous gel (cryogel) obtainable by the cryopolymerization process of the invention for the construction of filters, membranes or devices for the treatment of biological fluids.

A further object of the invention are therefore filters, membranes, or devices for the treatment of biological fluids which comprise materials obtained by the cryopolymerization process of the invention.

A sterile solution product bag includes sterilization grade filter integrated directly into the product bag such that microbial and particulate matter filtration can be performed using the filter directly at the point of fill. The filter can include a hollow fiber filter membrane contained in a stem connected to a bladder of the product bag.

The present invention relates to a method for measuring activity of HAO which comprises bringing HAO into contact with hydroxylamine in the presence of a tetrazolium salt. Further, the present invention also provides a method for culturing microorganisms which comprises culturing microorganisms in a storage container of a sample containing microorganisms installed separately in a liquid medium storage container, wherein the storage container of a sample containing microorganisms has pores.

Endotoxin is detected by electrochemical measurement. A detection device 15 of endotoxin detects endotoxin contained in a fluid to be tested (for example, a dialysate) specifically in the following manner. First, the fluid to be tested is brought into contact with an adsorbent 17 that adsorbs endotoxin to cause the adsorbent 17 to adsorb the endotoxin. Then, a basic solution is brought into contact with the adsorbent 17 to desorb the endotoxin. Electrochemical measurement of the basic solution containing the desorbed endotoxin is performed. The endotoxin can be detected by the electrochemical measurement with high sensitivity at low cost.

The present disclosure provides, among other things, systems for processing silk. Provided systems purify silk fibroin solutions without inducing conformational changes in the silk proteins. Provided systems concentrate silk fibroin solutions. The present disclosure also provides methods of purifying and concentrating silk fibroin solutions. Provided systems and methods are useful for processing silk fibroin for any application.

The present disclosure relates to a hemodialysis membrane for the treatment of restless leg syndrome (RLS), especially in severe and very severe cases and/or in patients which suffer from kidney failure and already receive hemodialysis. The present disclosure therefore also relates to methods of treating restless leg syndrome. The treatment and method encompasses using a hemodialysis membrane which is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 8.5 and 14.0 kD and a MWCO of between 55 kD and 130 kD.

A hemodialysis system is disclosed. The hemodialysis system includes a dialyzer and an online dialysate generation system comprising a water inlet line and a drain line. The hemodialysis system also includes a disposable set comprising a supply tube fluidly connected to online dialysate generation system and a dialysate pumping tube fluidly connected to the dialyzer. The hemodialysis system further includes a dialysis instrument comprising a dialysate pump head and a motor positioned and arranged to operate the dialysate pump head. The dialysis instrument operates the dialysate pump head to move fresh dialysate from the online dialysate generation system through the dialysate pumping tube to the dialyzer.

The present disclosure relates to semipermeable membranes which are suitable for blood purification, e.g. by hemodialysis, which have an increased ability to remove larger molecules while at the same time effectively retaining albumin. The membranes are characterized by a molecular retention onset (MWRO) of between 9.0 kD and 14.5 kD and a molecular weight cut-off (MWCO) of between 55 kD and 130 kD as determined by dextran sieving curves and can be prepared by industrially feasible processes excluding a treatment with salt before drying. The invention therefore also relates to a process for the production of the membranes and to their use in medical applications.